Advanced Molecular Solutions for Cancer Therapy

© 2024 by the authors; CC BY-NC-ND license

estrogen receptor β; coactivator; correlation; coregulation; prognosis; therapy; breast cancer; endometrial cancer; letrozole; mammalian target of rapamycin mTOR pathway; whole-exome sequencing; amino acid restriction; caloric restriction; methionine; HNSCC; SCCHN; cisplatin; amino acid transporter; SLC-family; cell vitality; low energy metabolism; aspirin; breast cancer; DDIT4; ACC1; CPT1A; renal cell carcinoma; molecular; pathology; treatment; clinical; adenovirus; adenoviral vector; oncolytic virus; midkine; metabolomics; prostate cancer; biomarkers; diagnosis; saliva; tumor markers; breast cancer; ovarian cancer; lung cancer; CA125; CA15-3; CA72-4; HE4; CEA; tezosentan; cancer; endothelin receptors; drug repurposing; papillary thyroid carcinomas; BRAF^V600E hot spot mutation; NADPH oxidase NOX4; biomarker; ERK5; MAPK7; BMK1; ERK5 inhibitor; anticancer; oncotherapy; imidazolium; breast cancer; HLA-G; Mexican population; rs66554220; 14-bp Ins/Del; western Mexico; stage IV; clinical; 2-methoxyestradiol; 2-MeO-E2; LTED cells; tubulin; G-1; breast cancer; amino acids; breast cancer; diagnosis; imaging; risk; prognosis; treatment; adeno-associated viral vectors; T cells; genetic engineering; CRISPR/Cas9; homology-directed repair; chimeric antigen receptor; dendritic cells; cytochalasin B; induced vesicles; antitumor vaccine; immunotherapy; GM-CSF; antigen presentation; cytotoxic effect; dendritic cells; immunotherapy; clinical trials; tumor-associated antigen; cancer; hypoxia-inducible factor 1; SP1; MYC; cancer; ADCY6; aldosterone-regulated sodium reabsorption; AP2A1; AVP; collecting duct acid secretion; CREB3L4; endocrine and other factor-regulated sodium reabsorption; ESR1; proximal tubule bicarbonate reclamation; vasopressin-regulated water reabsorption; breast cancer; miRNA profiling; cancer diagnostics; cancer therapy; ovarian cancer; OvCa; carboplatin resistance; ADRA2A; adrenoceptor alpha-2a; SOX10; neural crest cells; melanoma; neuroectodermal tumors; mesenchymal tumors; liver hepatocellular carcinoma; somatic mutations; neoantigens; immune checkpoint inhibitors; immunotherapy; blood; cancer; liquid biopsy; circulating tumor cells; circulating tumor DNA; cell-free DNA; microfluidic devices; neoplastic cells; n/a; microRNA; microarray; HER2; breast cancer; drug resistance